Alternative Dosing Of Niraparib To Decrease Dose Interruption In First Line Maintenance Treatment For Ovarian Cancer

NCT05961124 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Ovarian Cancer
Stage III Ovarian Cancer
Stage IV Ovarian Cancer
High Grade Ovarian Serous Adenocarcinoma

Interventions

DRUG: Niraparib

Sponsor

Sunnybrook Health Sciences Centre

Collaborators

[object Object]